Background-Secretoneurin is a neuropeptide located in nerve fibers along blood vessels, is upregulated by hypoxia, and induces angiogenesis. We tested the hypothesis that secretoneurin gene therapy exerts beneficial effects in a rat model of myocardial infarction and evaluated the mechanism of action on coronary endothelial cells. Methods and Results-In vivo secretoneurin improved left ventricular function, inhibited remodeling, and reduced scar formation. In the infarct border zone, secretoneurin induced coronary angiogenesis, as shown by increased density of capillaries and arteries. In vitro secretoneurin induced capillary tubes, stimulated proliferation, inhibited apoptosis, and activated Akt and extracellular signal-regulated kinase in coronary endothelial cells. Effects were abrogated by a vascular endothelial growth factor (VEGF) antibody, and secretoneurin stimulated VEGF receptors in these cells. Secretoneurin furthermore increased binding of VEGF to endothelial cells, and binding was blocked by heparinase, indicating that secretoneurin stimulates binding of VEGF to heparan sulfate proteoglycan binding sites. Additionally, secretoneurin increased binding of VEGF to its coreceptor neuropilin-1. In endothelial cells, secretoneurin also stimulated fibroblast growth factor receptor-3 and insulin-like growth factor-1 receptor, and in coronary vascular smooth muscle cells, we observed stimulation of VEGF receptor-1 and fibroblast growth factor receptor-3. Exposure of cardiac myocytes to hypoxia and ischemic heart after myocardial infarction revealed increased secretoneurin messenger RNA and protein. Conclusions-Our data show that secretoneurin acts as an endogenous stimulator of VEGF signaling in coronary endothelial cells by enhancing binding of VEGF to low-affinity binding sites and neuropilin-1 and stimulates further growth factor receptors like fibroblast growth factor receptor-3. Our in vivo findings indicate that secretoneurin may be a promising therapeutic tool in ischemic heart disease. (Circulation. 2012;126:2491-2501.)
C ongestive heart failure represents an increasing global health problem that occurs predominantly as a result of coronary artery disease. 1 Cardiac dysfunction after myocardial infarction (MI) results from 2 major mechanisms: loss of cardiac myocytes in the area of infarction and remodeling of the spared myocardium in the left ventricle (LV). Inadequate structural adaptation of the vascular bed in the area of cardiac myocyte hypertrophy accounts for the progression of LV dysfunction of the heart. Although ischemia induces endogenous myocardial angiogenesis, vascular growth is insufficient to maintain normal capillary density in the hypertrophied myocardium. Induction of neovascularization is recognized to be a valid approach to modify the pathological changes of ventricular remodeling. Gene transfer of growth factors known to induce angiogenesis such as vascular endothelial growth factor (VEGF), hepatocyte growth factor, sonic hedgehog, or basic fibroblast growth factor (bFGF) attenuates cardiac dysfunction after MI in animal models. [2] [3] [4] [5] In patients with coronary heart disease, randomized phase II and phase III gene therapy studies did not reach the primary end point, although in most studies signs of angiogenic bioactivity were observed. 6 -8 As in peripheral arterial disease, patient and study end point selection as well as determination of transgene expression will be important for planning future clinical studies evaluating treatment of ischemic cardiomyopathy. Additionally, a combination of growth factors or growth factors combined with cell therapy may be more promising than therapy with a single factor. 9 
Clinical Perspective on p 2501
In this study, we present a plasmid gene therapy approach based on secretoneurin, a neuropeptide of 33 amino acids in length, derived from secretogranin-II (SG2), a member of the chromogranin/secretogranin family, which induces angiogenesis. 10 -12 In a recent study, we showed that secretoneurin gene therapy restored tissue integrity, function, and perfusion in the mouse hindlimb ischemia model by induction of angiogenesis, arteriogenesis, and vasculogenesis. 13 We therefore hypothesized that secretoneurin may also exert beneficial effects in a rat model of MI. We provide evidence for improvement of cardiac function after MI by secretoneurin gene therapy in vivo and show a VEGF-dependent mechanism of secretoneurin action on human coronary artery endothelial cells (HCAECs) in vitro.
Methods

Construction of the Human Secretoneurin Expression Plasmid
Synthetic oligonucleotides encoding secretoneurin and a signal peptide were cloned into an expression plasmid vector, as has been described previously. 13 
Rat Model of MI
Protocols described in this study were approved by the Austrian Committee for the Care and Use of Laboratory Animals. MI was induced by ligation of the left anterior descending coronary artery, as described previously. 14 Animals received 100 g of secretoneurin plasmid or control plasmid intramyocardially.
Echocardiography
Echocardiograms were recorded under light anesthesia. Twodimensional directed M-mode and Doppler transthoracic echocardiographic studies were performed 3 days, 2 weeks, and 4 weeks after ligation with the use of an Acuson Sequoia echocardiography system (Acuson Corporation, Mountain View, CA) with a commercially available 15-MHz linear-array transducer system (AcuNav, Acuson Corporation). 15 Data were analyzed with the use of software resident on the ultrasonograph by an experienced researcher who was blinded to the treatment.
Hemodynamic Analysis
Cardiac hemodynamics were measured with a 1.4F catheter (Millar Instruments), as described previously. 16 Rats were anesthetized and placed in the supine position. After intubation, rats were mechanically ventilated, and the anterior chest wall was opened. During direct insertion of the catheter into the LV, ventilation was discontinued. Recordings of dP/dt and were performed with the rats under ECG monitoring in a stable state during different cardiac cycles.
Cell Culture and In Vitro Assays
The following cell lines were used and purchased from Promo Cell: HCAECs, human coronary artery smooth muscle cells (HCASMCs), and human cardiac myocytes. Migration and tube formation assays, Western blotting, and immunoprecipitation were performed as described previously 13 or in detail in Methods in the online-only Data Supplement.
Receptor Tyrosine Kinase Profiler and Immunoprecipitation
Human phospho-receptor tyrosine kinase (RTK) array kits (R&D, ARY001) were used for investigation of receptors involved in HCAEC and HCASMC signaling with secretoneurin as suggested by the manufacturer.
I-VEGF Binding Assays on HCAECs
For binding assays, HCAECs were cultured in 24-well plates and incubated with 250 000 cpm 125 I-VEGF (PerkinElmer), as detailed in the online-only Data Supplement.
Statistical Analysis
All results are expressed as meanϮSEM. Statistical comparisons between 2 groups were performed by Student t test. Multiple groups were analyzed by a 1-way ANOVA test followed by appropriate post hoc tests to determine statistical significance. P values Ͻ0.05 were considered statistically significant. All experiments were repeated at least in triplicate.
For further details regarding materials and methods, see the online-only Data Supplement.
Results
In Vivo Expression of Plasmid-Derived Secretoneurin
After intramyocardial injection of secretoneurin plasmid, real-time polymerase chain reaction with plasmid-specific primers (detecting plasmid-derived secretoneurin but not endogenous secretoneurin) was performed from muscle extracts. We observed messenger RNA of plasmid-derived secretoneurin 7 and 14 days after injection but not 28 days after application ( Figure 1A ).
Secretoneurin Improves Cardiac Function After MI
To test whether secretoneurin gene therapy of ischemic myocardium improves cardiac function, echocardiographic investigations were performed 4 weeks after left anterior descending coronary artery ligation and treatment (nϭ12 per group). We observed significant improvement of LV ejection fraction (LV ejection fraction: secretoneurin plasmid, 64.4Ϯ3.1% versus control plasmid, 40.3Ϯ2.7%, Pϭ0.00001; sham operation, 61.9Ϯ3.5%) and LV fractional shortening (secretoneurin plasmid, 39.8Ϯ4.6% versus control plasmid, 25.1Ϯ4.2%, Pϭ0.04; sham operation, 41.2Ϯ5.1%) in the secretoneurin-treated group compared with the control group ( Figure 1B) . Additionally, LV end-diastolic diameter (secretoneurin plasmid, 9.1Ϯ0.6 mm versus control plasmid, 10.5Ϯ0.3 mm; Pϭ0.04) and LV end-systolic diameter (secretoneurin plasmid, 6.5Ϯ0.6 mm versus control plasmid, 9.1Ϯ0.5 mm; Pϭ0.002) were significantly reduced in rats receiving secretoneurin plasmid compared with control treat-ment ( Figure 1C ). In addition, we performed cardiac hemodynamic measurements 4 weeks after MI. Both LV ϩdP/dt and ϪdP/dt were significantly improved in the secretoneurintreated animal group (ϩdP/dt, 5726Ϯ458 mm Hg/s; ϪdP/dt, Ϫ3830Ϯ435 mm Hg/s) versus control plasmid (ϩdP/dt, 3875Ϯ365 mm Hg/s; Pϭ0.004, secretoneurin plasmid versus control plasmid; ϪdP/dt, Ϫ2656Ϯ357 mm Hg/s; Pϭ0.04, secretoneurin plasmid versus control plasmid; nϭ16 per group; Figure 1D ; sham: ϩdP/dt, 6790Ϯ367). Additionally, values were determined and revealed significant improvement in the secretoneurin plasmid-treated animal group (22Ϯ1.9; Pϭ0.002 versus control plasmid) compared with control (33Ϯ1.8; sham operation, 19Ϯ1.2; nϭ5 per group). These data indicate that intramyocardial administration of secretoneurin plasmid exerts a favorable impact on LV function and LV remodeling in rats after MI.
Additionally, secretoneurin therapy inhibited organ congestion, as shown by reduced heart and lung weight compared with body weight (Table I in 
Secretoneurin Induces Myocardial Angiogenesis and Arteriogenesis In Vivo
Vascular structures in ischemic myocardium (nϭ15 per group) were visualized by immunofluorescent staining for rat endothelial cell antigen ( Figure 2A ) and ␣-smooth muscle actin ( Figure 2B ). Rat endothelial cell antigen-positive capillaries showed significantly higher blood vessel density (number of capillaries per high-power field) in peri-infarct regions in secretoneurin-treated animals compared with control animals (secretoneurin plasmid, 381.7Ϯ100.1 versus control plasmid, 277.9Ϯ54.9; Pϭ0.0005), and staining with anti-␣-smooth muscle actin showed higher density for arteries and arterioles in the secretoneurin treatment group (secretoneurin plasmid, 9.9Ϯ3.0 versus control plasmid, 5.2Ϯ1.2; Pϭ0.00004) ( Figure 2C ). These observations indicate induction of angiogenesis and arteriogenesis in the infarct border zone by secretoneurin gene therapy. Figure 3A shows Masson trichrome-stained myocardial sections from control plasmid-and secretoneurin plasmidtreated rats 4 weeks after left anterior descending coronary artery ligation. Treatment with secretoneurin plasmid resulted in a remarkable reduction of fibrosis in the LV after MI compared with controls. Figure 3B shows the percentage of fibrosis in hearts after permanent left anterior descending coronary artery occlusion. Hearts receiving secretoneurin gene therapy exhibited a significant reduction in fibrosis (secretoneurin plasmid, 21.7Ϯ1.6%) compared with controls (control plasmid, 35.4Ϯ2.8%; Pϭ0.0007; nϭ13). 
Secretoneurin Reduces Fibrosis After MI
In Vitro Effects of Secretoneurin on Migration, Angiogenesis, and Apoptosis of HCAECs
Secretoneurin caused a dose-dependent induction of chemotaxis in HCAECs with a maximum effect at 100 ng/mL (relative chemotactic index, 2.4Ϯ0.2; Pϭ0.0009 versus control; Figure 4A ). Blockade of secretoneurin with a specific neutralizing antibody (secretoneurin antibody) completely inhibited secretoneurin-mediated HCAEC migration, indicating specificity of the observed effect (relative chemotactic index for secretoneurin 100 ng/mLϩsecretoneurin antibody, 1.4Ϯ0.1; Pϭ0.009 versus secretoneurin 100 ng/mL). Interestingly, the chemotactic effect of secretoneurin was also inhibited by a VEGF antibody (relative chemotactic index for secretoneurin 100 ng/mLϩVEGF antibody, 1.4Ϯ0.1; Pϭ0.006 versus secretoneurin 100 ng/mL) and the mitogen-activated protein kinase (MAPK) inhibitor PD98.059 (PD) (relative chemotactic index for secretoneurin 100 ng/mLϩPD, 1.3Ϯ0.01; Pϭ0.005 versus secretoneurin 100 ng/mL).
Secretoneurin-induced angiogenesis in vitro was demonstrated by increase in capillary-like tube formation in a Matrigel assay with HCAECs with a maximum effect at 10 ng/mL (relative tube formation, 2.2Ϯ0.1; Pϭ0.00002 versus control; Figure 4B ). Addition of secretoneurin antibody abolished secretoneurin-induced tube formation (1.1Ϯ0.1; Pϭ0.001 versus secretoneurin 100 ng/mL), indicating specificity of observed effects. In accord with the observation in the migration assay, secretoneurin-induced tube formation was also impaired by VEGF antibody (relative tube formation, 1.3Ϯ0.1; Pϭ0.005 versus secretoneurin 100 ng/mL). PD also inhibited secretoneurin-induced effects (relative tube formation, 1.5Ϯ0.1; Pϭ0.007 versus secretoneurin 100 ng/mL), indicating a MAPK-dependent signaling of secretoneurin.
To investigate the effect of secretoneurin on HCAEC apoptosis, cells were starved and stained with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and 4Ј,6-diamidino-2-phenylindole (DAPI). 
Secretoneurin Signaling in HCAECs
Secretoneurin signaling was evaluated by Western blotting, which revealed activation of MAPK and phosphatidylinositol 3-kinase/Akt as judged by phosphorylation of extracellular signal-regulated kinase (ERK) and Akt. In HCAECs, secretoneurin stimulated MAPK phosphorylation at a concentration of 100 ng/mL, starting after 20 minutes with a continuing, long-lasting stimulation until 4 hours. Akt was activated by secretoneurin 100 ng/mL after 40 minutes with a 4-hour duration ( Figure 5A ). As observed in tube formation and migration assays, secretoneurin-induced effects on ERK activation were again blocked by VEGF antibody ( Figure 5B ).
Secretoneurin Stimulates VEGF Receptors
Because secretoneurin-mediated in vitro effects were blocked by a VEGF antibody, secretoneurin-induced signaling in HCAECs was further investigated with the use of RTK profiler assays (R&D). Results show an activation of VEGF receptor-1 and -2 (VEGFR1, VEGFR2, respectively) after a 40-minute treatment with secretoneurin 100 ng/mL ( Figure 6A ). This effect again could be blocked by VEGF antibody (1:500 dilution; Figure 6B ), indicating that secretoneurin-induced VEGF receptor activation depends on endogenous VEGF.
Immunoprecipitation of HCAEC lysates with VEGFR2 antibody and immunoblotting for phosphotyrosine confirmed findings of the RTK profiler and revealed secretoneurin-induced VEGFR2 phosphorylation after 120 minutes ( Figure 6C ).
Western blot analysis of phosphorylated VEGFR2 additionally showed an increase of VEGF-induced (50 ng/mL) VEGFR2 activation by secretoneurin, comparable to the aforementioned effect of heparin (1 g/mL), as shown in Figure 6D . These data indicate that secretoneurin stimulates VEGF receptor activation via a VEGF-dependent mechanism.
Immunohistochemical staining for phospho-VEGFR2 could be found only in ischemic rat hearts treated with secretoneurin plasmid 3 days after MI ( Figure 6E ) but not in control animals (data not shown).
In HCASMCs, we found activation of VEGFR1 and fibroblast growth factor receptor-3 (FGFR3) by secretoneurin 100 ng/mL after 40 minutes ( Figure 6F ). In contrast to HCAECs, however, we were not able to block secretoneurinmediated effects by a neutralizing VEGF antibody (as demonstrated with a chemotaxis assay in HCASMCs; Figure IIA in the online-only Data Supplement).
Without starvation of HCAECs before stimulation with secretoneurin, a different picture was observed in RTK profiler assays: VEGFR1 and VEGFR2 were still stimulated by secretoneurin, but activation of FGFR3 and insulin-like growth factor-1 receptor was also detectable ( Figure 6G ). To evaluate whether FGF also plays a role in secretoneurinmediated effects on HCAECs, we inhibited bFGF with a neutralizing antibody but were not able to block secretoneurin-induced in vitro angiogenesis, in contrast to inhibition of VEGF ( Figure IIB in the online-only Data Supplement). Therefore, secretoneurin-induced VEGF signaling in HCAECs was further evaluated.
To test the hypothesis that VEGFR2, which has been reported to be mainly responsible for angiogenic effects within the VEGF receptor family, is involved in secretoneurin signaling in HCAECs, a specific VEGFR2 inhibitor, SU1498, was tested. SU1498 (40 mol/L) showed inhibition of secretoneurin-induced MAPK activation after 20, 40, and 60 minutes, indicating that secretoneurin-induced MAPK activation is mediated by VEGFR2 ( Figure 7A ).
Inhibition of secretoneurin-mediated in vitro angiogenesis by SU1498 was demonstrated by Matrigel assays: After addition of SU1498 (10 or 40 mol/L; Figure 7B ), secretoneurin-induced capillary tube formation was completely blocked (secretoneurinϩSU1498, 10 mol/L 1.1Ϯ0.03 versus secretoneurin, 2.1Ϯ0.2 mol/L; Pϭ0.0001), indicating that secretoneurin-induced in vitro angiogenesis is also mediated by VEGFR2. 5-Bromo-2Ј-deoxyuridine assays performed with HCAECs identified VEGFR2 and the MAPK pathway as essential modulators for secretoneurin-induced HCAEC proliferation. Both PD and SU1498 abolished secretoneurin-induced relative proliferation compared with secretoneurin 100 ng/mL (secretoneurin, 1.42Ϯ0.04 versus secretoneurinϩPD, 0.58Ϯ0.04, Pϭ0.00007; secretoneurin versus secretoneurinϩ SU1498, 0.69Ϯ0.07, Pϭ0.00001; Figure 7C ).
Secretoneurin Increases VEGF Binding to HCAECs, Heparin, and Neuropilin-1
To determine the mechanism of secretoneurin-induced VEGF receptor stimulation, we hypothesized that secretoneurin might interact with VEGFR2 and its coreceptor neuropilin-1 or with heparan sulfate proteoglycans, shown to be necessary for VEGFR2 activation. 17 However, we could not find direct binding of secretoneurin either to VEGFR2 or to neuropilin-1 (data not shown) or to heparin with the use of heparin-coated Sepharose columns (data not shown). Figure 8A ). On the basis of the effect of secretoneurin at a concentration of 100 ng/mL, we performed saturation studies in the presence or absence of secretoneurin, with increasing amounts of 125 I-VEGF starting from 2.6 fmol/mL to a maximum concentration of 523 fmol/mL. Because secretoneurin did not affect binding of VEGF to VEGFR2 ( Figure IIIA in the online-only Data Supplement), we further hypothesized that secretoneurin might stimulate binding of VEGF to heparan sulfate proteoglycans of the extracellular matrix. Therefore, a heparin-bovine serum albumin complex, as described previously, 18 was used for analyzing the binding of VEGF to heparin in the presence of secretoneurin. Figure 8B illustrates a significant increase in 125 I-VEGF binding to heparin, when secretoneurin 10 or 100 ng/mL was added to the binding buffer (secretoneurin 10 ng/mL, 1.09Ϯ0.01 pmol and secretoneurin 100 ng/mL, 1.12Ϯ0.001 pmol versus 125 I-VEGF, 0.99Ϯ0.01 pmol; Pϭ0.0003 and Pϭ0.00007, respectively). A similar effect was observed when heparin-coated Sepharose beads were used ( Figure IIIB in the online-only Data Supplement). To ascertain whether binding to heparan sulfate proteoglycans is responsible for increased secretoneurin-induced VEGF binding to HCAECs and secretoneurin-induced effects on HCAECs, we used heparinase I and heparinase III, which in combination digest heparin as well as heparan sulfates. Preincubation of cells with the mixture of heparinases resulted in complete loss of secretoneurin-mediated increase in VEGF binding ( 125 I-VEGFϩsecretoneurinϩheparinase, 1.77Ϯ0.09 versus 125 I-VEGFϩsecretoneurin, 2.09Ϯ0.08; Pϭ0.027; Figure 8C ). The finding that secretoneurin-induced effects depend on heparan sulfate proteoglycans was confirmed by the observations that pretreatment of HCAECs . HCAECs were stimulated with SN 100 ng/mL for different time periods, and cell lysates were collected and immunoprecipitated for VEGFR2. After blotting, membranes were probed with anti-phosphotyrosine antibody. SN induced activation of VEGFR2 after 120 minutes. D, SN effects on VEGF-mediated VEGFR2 activation are comparable to those of heparin (Hep). HCAECs were treated with control medium, SN 100 ng/mL, and VEGF 50 ng/mL in combination with either heparin 1 g/mL or SN 100 ng/mL. Levels of VEGFR2 phosphorylation were determined by Western blot analysis with the use of a specific phospho-VEGFR2 antibody. SN, like heparin, stimulated VEGF-mediated VEGFR2 phosphorylation. E, VEGFR2 phosphorylation in vivo. Frozen sections of rat heart 3 days after myocardial infarction and SN gene therapy showed positive staining for phospho-VEGFR2. F, Treatment of human coronary artery smooth muscle cells with SN induced phosphorylation of VEGFR1 and fibroblast growth factor receptor-3 (FGFR3). Human coronary artery smooth muscle cells were stimulated with SN 100 ng/mL for 40 minutes, and cell lysates were used for profiler assays. In comparison to untreated cells, SN induced phosphorylation of VEGFR1 and FGFR3. G, SN also activates FGFR3 and insulin-like growth factor-1 receptor (IGF-1R) in HCAECs. In unstarved HCAECs, profiler assays revealed stimulation of FGFR3 and IGF-1R with SN 100 ng/mL after 40 minutes, in addition to the already observed phosphorylation of VEGFR1 and VEGFR2.
with heparinases I and III inhibited secretoneurin-mediated MAPK activation ( Figure 8D ) and antiapoptotic effects (secretoneurin relative to control, 0.57Ϯ0.02 versus secretoneurinϩheparinase, 0.93Ϯ0.05, Pϭ0.0002; secretoneurin versus secretoneurinϩVEGF antibody, 0.97Ϯ0.02, Pϭ0.00003; secretoneurin versus secretoneurinϩPD, 0.85Ϯ0.05; Pϭ0.0008; Figure 8E ).
Although we found no effect of secretoneurin on binding of VEGF to its receptor VEGFR2 ( Figure I-VEGF, 504Ϯ16.7 fmol/g; Pϭ0.012; Figure 8F ).
Discussion
The main finding of our work is that gene therapy with the angiogenic factor secretoneurin improves outcome in a rat MI model in terms of LV function (evaluated by echocardiography and invasively by cardiac catheterization), LV remodeling, and scar formation. These effects were accompanied by an increase of capillary and arterial density in the infarct border zone, and we therefore hypothesized that this beneficial effect was largely due to induction of angiogenesis by secretoneurin, as shown before in other in vivo models, 10 especially in the hindlimb ischemia model. 13 As in this previous work, gene therapy was performed after ligation of the artery by intramuscular plasmid injection, and plasmidderived secretoneurin was detectable for 2 weeks. Although we cannot exclude direct effects of secretoneurin on cardiac myocytes, we did not observe regulation of classic angiogenic factors such as VEGF by secretoneurin on these cells under either normoxic or hypoxic conditions (data not shown). First experiments also showed no effect of secretoneurin on RTKs in cardiac myocytes, as observed in this study for HCAECs and HCASMCs. Additionally, an intermediate time point after MI (14 days) showed a trend toward an increase, although it was not significant, of myocardial function and of capillary density by secretoneurin, indicating that full induction of angiogenesis is necessary for the effects of secretoneurin on myocardial function ( Figure IVA through IVC in the online-only Data Supplement). As in skeletal muscle cells, 19 however, we also found in cardiac myocytes (but not in coronary endothelial cells) that prolonged hypoxia increases secretoneurin at messenger RNA and protein levels (Figure VA through VC in the online-only Data Supplement), which may indicate that secretoneurin, like other angiogenic factors, is increased as a physiological response to hypoxia in these cells to counteract the decrease of oxygen supply by the growth of new blood vessels. We also observed increased secretoneurin messenger RNA and protein in vivo after MI by polymerase chain reaction and immunofluorescence ( Figure  VIA and VIB in the online-only Data Supplement). In regard to the reduction in scar formation/fibrosis, we did not find effects of secretoneurin on human cardiac fibroblasts in vitro (regulation of secretoneurin by hypoxia, influence on cell proliferation or apoptosis by secretoneurin; Figure VIIA through VIIC in the online-only Data Supplement), and therefore we hypothesize that reduction of fibrosis is due to less damage of cardiac myocytes in the secretoneurin group rather than an inhibitory effect of secretoneurin on this process.
An interesting finding of our in vitro studies was that secretoneurin-induced effects on HCAEC migration, tube formation, proliferation, antiapoptosis, and ERK activation were blocked by a neutralizing VEGF antibody, whereas a bFGF antibody had no effect, at least on in vitro tube formation ( Figure IIB in the online-only Data Supplement). This VEGF-dependent effect is in contrast to our data in human umbilical vein endothelial cells 10 ( Figure VIII in the online-only Data Supplement), in which we did not observe stimulation of VEGF receptors by secretoneurin, indicating specificity of this observed effect for coronary arterial endothelial cells. The reason for this difference must be evaluated in future studies, and because we found that secretoneurin stimulates binding of VEGF to heparan sulfate proteoglycans, perhaps the composition of the extracellular matrix and/or differences in growth factors stored in the matrix are responsible for these observations. Nevertheless, to investigate whether secretoneurin stimulates RTKs, we used a commer- . D, Heparinase inhibits SN-mediated mitogen-activated protein kinase (MAPK) activation. After preincubation of HCAECs with heparinase, cells were stimulated with SN 100 ng/mL for different time periods, and lysates were processed for Western blotting. E, VEGF antibody (VEGF-Ab), PD98.059 (PD), and heparinases abrogate SN-induced antiapoptotic effects. HCAECs were starved overnight in medium without supplementsϮSN 100 ng/mL, PD (10 mol/L), VEGF-Ab, and heparinase. VEGF 50 ng/mL served as positive control (*PϽ0.001, SN vs control; **PϽ0.001, SNϩheparinase, SNϩVEGF-Ab, and SNϩPD vs SN 100 ng/mL; nϭ4). F, SN increases binding of 125 I-VEGF to NP1. Maxisorb tubes were coated with recombinant human NP1, and binding assays in the presence or absence of SN 10 and 100 ng/mL were performed. SN 100 ng/mL significantly increased cially available profiler and found that secretoneurin stimulates phosphorylation of VEGFR1, VEGFR2, FGFR3, and insulin-like growth factor-1 receptor in coronary endothelial cells as well as VEGFR1 and FGFR3 in coronary smooth muscle cells. Additionally, stimulation of VEGFR2 was observed after MI and secretoneurin gene therapy in vivo by immunohistochemistry. These findings indicate that the angiogenic neuropeptide secretoneurin stimulates several RTKs in coronary vascular cells, which may explain the robust effects observed in our study. In particular, the fact that different RTKs shown to be important for angiogenesis such as VEGF and FGF receptors were activated by secretoneurin may be important because a recently published work was able to show that a combination of angiogenic growth factors (ie, FGF and hepatocyte growth factor) produced a more potent and sustained effect in the corneal angiogenesis and MI models compared with the single factors. 9, 20 Similar effects were reported previously with the combination of bFGF and platelet-derived growth factor. 21 Additionally, a close interaction between VEGF and FGF pathways (FGF-dependent regulation of VEGFR2) was shown to be necessary for postischemic neovascularization. 22 Therefore, it is conceivable that combinations of growth factors or stimulation of several different RTKs exerts additive, longlasting effects on therapeutic angiogenesis. This is also of particular interest for clinical studies of therapeutic angiogenesis, in which application of a single growth factor did not show positive results in phase III studies. 23, 24 Because VEGFR2 is considered to be the pivotal receptor for endothelial cell survival and proliferation and for angiogenesis 25 and we found that the effects of secretoneurin on endothelial cells were blocked by a neutralizing VEGF antibody and by a VEGFR2 blocker (SU1498), we further characterized the mechanism of secretoneurin-induced action in regard to VEGFR2 signaling. Activation of VEGFR2 by VEGF is dependent on heparan sulfate proteoglycans, 20 and matrix-bound VEGF was reported to activate more sustained VEGFR2 stimulation. 26 VEGF signaling via VEGFR2 is also enhanced by a coreceptor (ie, neuropilin-1). 27 We therefore hypothesized that secretoneurin may bind to one of these VEGF receptors, but we were not successful in demonstrating direct binding of secretoneurin to VEGF itself, to VEGFR2, to neuropilin, or to heparin (data not shown). We therefore analyzed whether secretoneurin increases binding of VEGF to its receptors, as was shown for heparin, which stimulates VEGF binding to VEGFR2. 28 Indeed, we found that secretoneurin stimulated binding of VEGF to coronary endothelial cells, and this effect was abolished when cells were preincubated with heparinase, indicating that secretoneurin stimulates binding of VEGF to heparan sulfate proteoglycans. This finding was corroborated by the fact that secretoneurininduced ERK activation and antiapoptotic effects were also blocked by heparinase. Secretoneurin did not increase binding of VEGF to VEGFR2 ( Figure IIIA in the online-only Data Supplement) but stimulated binding of VEGF to its coreceptors heparin and neuropilin-1, indicating that secretoneurin-induced effects are mediated by increased VEGF binding to neuropilin-1 and heparan sulfate proteoglycans. It is known that C-terminal basic amino acids of VEGF are responsible for binding of VEGF-165 to heparin. Because secretoneurin contains several acidic amino acids, we plan to synthesize different secretoneurin derivatives to characterize the responsible sequence of secretoneurin necessary for increased binding of VEGF to heparin in future studies.
In contrast to endothelial cells, we were not able to block secretoneurin-induced effects in HCASMCs by a neutralizing VEGF antibody ( Figure IIA in the online-only Data Supplement), allowing the assumption that secretoneurin acts via a different mechanism on these cells. Because FGFR3 was also activated by secretoneurin in HCASMCs, we are planning to analyze the role of FGF in secretoneurin-mediated effects in smooth muscle cells as well as in endothelial cells.
Summarizing our data, we found that secretoneurin acts as an endogenous enhancer of VEGF binding to its coreceptor neuropilin-1 and to heparan sulfate proteoglycan binding sites. We would like to propose secretoneurin as a novel agent in the treatment of ischemic cardiomyopathy for several reasons. Secretoneurin acts as stimulator of several growth factor RTKs known to play essential roles in angiogenesis (ie, VEGFR2 and FGFR3) in the coronary vasculature. Furthermore, secretoneurin also affects coronary artery smooth muscle cells, as was shown in this and previous studies, 10, 13 to induce growth of smooth muscle cell-covered blood vessels that are known to be more stable than capillaries. Finally, secretoneurin improved LV function and LV remodeling in an in vivo model of MI. Future studies also should be able to determine appropriate vectors for efficient delivery of this peptide in large-animal models and in human trials.
